Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the "no more metallic cages" multicentre pilot experience
Alfonso Ielasi, Tadashi Miyazaki, Salvatore Geraci, Luca Testa, Mohamed Abdel-Wahab, Hiroyoshi Kawamoto, Neil Ruparelia, Takao Sato, Giuseppe Caramanno, Francesco Bedogni, Maurizio Tespili, Antonio Colombo, Azeem Latib, Alfonso Ielasi, Tadashi Miyazaki, Salvatore Geraci, Luca Testa, Mohamed Abdel-Wahab, Hiroyoshi Kawamoto, Neil Ruparelia, Takao Sato, Giuseppe Caramanno, Francesco Bedogni, Maurizio Tespili, Antonio Colombo, Azeem Latib
Abstract
Aims: Our aim was to assess the feasibility and results of a hybrid approach with a bioresorbable scaffold (BRS) plus a drug-coated balloon (DCB) for the treatment of diffuse coronary artery disease (CAD).
Methods and results: A retrospective analysis was performed on consecutive patients with diffuse de novo or in-stent restenosis treated with BRS implantation (larger proximal segment) and DCB inflation (smaller distal segment or bifurcation side branch). Endpoints were procedural success, then ischaemia-driven target lesion revascularisation (ID-TLR) and BRS/DCB segment thrombosis rates at follow-up. A total of 42 consecutive patients were treated with the hybrid strategy. Mean patient age was 62±1.02 years, while 12 (28.6%) patients were diabetics. Mean BRS and DCB length were 28.0±5.1 mm and 25.8±8.8 mm, respectively. Procedural success was obtained in all patients, but three (7.3%) patients required bail-out scaffolding for DCB-related dissection. At a median follow-up of 12 months (IQR: 6-18), there were no cases of cardiac death, target vessel myocardial infarction, or BRS/DCB segment thrombosis. ID-TLR occurred in two (4.7%) BRS-treated segments.
Conclusions: Our data in consecutive patients with diffuse CAD suggest that a hybrid strategy using BRS and DCB in different segments of the diseased vessel is feasible and associated with encouraging clinical outcomes.
Source: PubMed